Resources

Now What with Injectable LEN for PrEP?

Since results of the PURPOSE efficacy trials were announced in 2024, injectable lenacapavir for PrEP (LEN) has generated enormous excitement and opportunity – and frustration. By the end of 2024, Gilead Sciences provided six voluntary licenses to generic manufacturers and submitted multiple regulatory filings, and the Global Fund and PEPFAR committed to an ambition to reach two million people over three years, pending regulatory approvals and WHO guidelines. It seemed like bold ambition – and it was, compared to the previous launches of oral PrEP, vaginal ring and CAB.

But this ambition was always defined as a floor, not a ceiling. In April 2026, the collaboration increased the goal to reach three million people over three years with LEN for PrEP. In July 2025, AVAC published a first edition of Now What with Injectable LEN for PrEP, outlining priorities to ensure introduction moved swiftly. Now, in this update, AVAC is calling for a new minimum floor: reach three million in two years (2026-2027). No less and no slower, with a push for more and faster.

Re: Imminent Threats to HIV Research: Organizational Sign-On Letter to Congress

AVAC joined dozens of other organizations in urging Congress to address imminent threats to HIV research from the Administration. These threats are part of a broader political effort to undermine the National Institutes of Health (NIH) and...

Investing in Biomedical Innovation for Health and Economic Growth

This Financial Times webinar, hosted in partnership with ViiV Healthcare, brought together policymakers, funders, researchers, philanthropies and industry leaders to explore how to keep medical innovation moving forward. The conversation examined...

Injectable PrEP Regulatory Approvals

This graphic tracks regulatory approvals for injectable cabotegravir and lenacapavir for PrEP as of October 2026.

ARV-Based and Multipurpose Prevention Technology R&D Pipeline

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development.

Lenacapavir Regulatory Approval

Regulatory approvals, pending decisions, and appeals as of September 2026.

HIV Prevention Pipeline: Products to Watch

From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.

Aftershocks Roundtable: How do we rebuild our HIV and public health infrastructure?

Please join TCA and IAPAC’s Dr. José M. Zuniga – author of the new book “Aftershocks: Trump 2.0, Public Health, and Our Better Angels” – and a dynamic panel to discuss the profound disruption of public health systems over the past almost...

AVAC’s Remarks to the NIAID Council and the ARAC on the proposed NIAID reorganization

AVAC delivered a public comment for the record at the NIAID Council meeting raising concerns about the proposed NIAID reorganization and its potential impact on HIV research, including the elimination of the Division of Clinical Research, disruption...